检索结果-南通市图书馆

Hippophae rhamnoides *** extract enhances cell proliferation and neuroblast differentiation through upregulation of intrinsic factors in the dentate gyrus of the aged gerbil

引用

Chinese Medical Journal 2014年第23期127卷 4006-4011页

作者： Ji Hyeon Ahn Bai Hui Chen Joon Ha Park In Hye Kim jeong-Hwi Cho Jae-Chul Lee Bing Chun Yan Jung hoon Choi In Koo Hwang Ju-Hee Park Sang-No Han Yun Lyul Lee Myong Jo Kim Moo-Ho Won Department of Neurobiology School of Medicine Kangwon National University Chuncheon 200-701 South Korea Department of Physiology College of Medicine Hallym University Chuncheon 200-702 South Korea Institute of Integrative Traditional & Western Medicine Medical College Yangzhou University Yangzhou Jiangsu 225001 China Department of Anatomy College of Veterinary Medicine Kangwon NationaL University Chuncheon 200-701 South Korea Department of Anatomy and Cell Biology College of Veterinary Medicine and Research Institute for Veterinary Science Seoul National University Seoul 151-742 South Korea Samsung Herb Medicine Company Limitedl 304 BIO-ldong ChunCheon Biotechnology Innovation Center Chuncheon 200-957 South Korea Oriental Bio-herb Research Institute Kangwon National University Chuncheon 200-701 South Korea

Background Hippophae rhamnoides L.（HL） exerts antioxidant activities against various oxidative stress *** this study,we investigated effects of extract from HL leaves （HLE） on cell proliferation and neuroblast differentiation in the subgranular zone （SGZ） of the dentate gyrus （DG） of aged *** Aged gerbils （24 months） were divided into vehicle （saline）-treated-and *** vehicle and HLE were orally administered with 200 mg/kg once a day for 20 days before *** proliferation and neurobiast differentiation were examined in the DG using Ki67 and doublecortin （DCX）,*** also observed changes in immunoreactivities of superoxide dismutase 1 （SOD1） and superoxide dismutase 2 （SOD2）,brain-derived neurotrophic factor （BDNF）,and phospho-glycogen synthase kinase-3-beta （p-GSK-3β） to examine their relation with neurogenesis using *** The administration of HLE significantly increased the number of Ki67-positive cells and DCX-positive neuroblasts with well-developed processes in the SGZ of the DG of the *** addition,immunoreactivities of SOD1,SOD2,BDNF,and p-GSK-3β were significantly increased in granule and polymorphic cells of the DG in the HLE-treated-group compared with those in the *** HLE treatment significantly increased cell proliferation and neuroblast differentiation,showing that immunoreactivities of SOD1,SOD2,BDNF,and p-GSK-3β were significantly increased in the *** indicate that increased neuroblast differentiation neurogenesis may be closely related to upregulation of SOD1,SOD2,BDNF,and p-GSK-3β in aged gerbils.

关键词： aging antioxidants dentate gyrus hippophae rhamnoides extract neurogenesis neurotrophic factors

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

韩国基于风险的大坝安全管理研究现状

引用

大坝与安全 2015年第6期29卷 75-79页

作者： Dong-hoon Shin Ki-Young Kim jeong-Yeol Lim 崔弘毅许传桂 Korea Water Resources Corporation 不详

大坝一旦完建,大坝业主和大坝工程师的首要职责就是通过实施检查和安全评估对大坝进行合理的维护,这也是相关条例、法规和法案的要求。之前,韩国的大坝安全评估都是基于规范和定性的方法,没有考虑自然的不确定性。最近,基于风险的大坝... 详细信息

大坝一旦完建,大坝业主和大坝工程师的首要职责就是通过实施检查和安全评估对大坝进行合理的维护,这也是相关条例、法规和法案的要求。之前,韩国的大坝安全评估都是基于规范和定性的方法,没有考虑自然的不确定性。最近,基于风险的大坝安全管理被认为是大坝安全管理下一代范例中真正可靠的选择。笔者介绍了目前传统的制度体系在大坝安全管理中是如何运作的,以及基于风险的大坝安全管理是如何作为一种新的大坝安全范例来引进的。笔者还会介绍一些大坝安全导则和法规来追述韩国大坝安全管理的变化历史。最后,笔者将简要介绍某大坝在大坝风险评估方面开展的工作,这是新的大坝安全范例。

关键词：韩国大坝安全管理风险

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Impact of clopidogrel treatment on platelet function and thrombogenecity in diabetic patients undergoing elective coronary stenting

引用

Journal of Diabetes Mellitus 2012年第2期2卷 153-164页

作者： Anand Singla Kevin P. Bliden Young-hoon jeong Joseph DiChiara Mark J. Antonino Denny P. Mathew William C. Muse Katrina Abadilla Tania Gesheff Udaya S. Tantry Paul A. Gurbel Sinai Center for Thrombosis Research Baltimore USA

High platelet reactivity (HPR) and suboptimal response to dual antiplatelet therapy (DAPT) may explain high recurrent rates of ischemic events in Type II diabetes mellitus (DM) patients undergoing percutaneous coronary intervention (PCI). The aim of this study was to examine the effect of clopidogrel on platelet reactivity, and thrombogenecity between DM and non-DM PCI-treated patients (n = 138). Patients were categorized according to clopidogrel treatment and DM status. Patients received a maintenance-dose clopidogrel of 75 mg/d (C75 group, n = 72) or a 600 mg clopidogrel loading-dose in clopidogrel na?ve patients (C600 group, n = 66). Platelet function was assessed by thrombelastography, flow cytometry, VerifyNowTM aspirin assay and light transmittance aggregometry (LTA). Aspirin response was similar between treatments and DM status. In the C75 group, DM patients had higher 5 and 20 μM ADP-, 2 μg/ml collagen-induced LTA;and p-selectin expression compared to non-DM patients (p ≤ 0.05 for all). DM patients in the C600 group had higher 5 and 20 μM ADP-induced LTA post dosing (p p 12 receptor antagonists.

关键词： Diabetes Clopidogrel Platelet Reactivity Hypercoagulability

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma:amulticenter,retrospective analysis

引用

Cancer Communications 2021年第3期41卷 275-278页

作者： Jun Ho Yi Seok Jin Kim Dok Hyun Yoon Cheolwon Suh Myung Hee Chang Deok Hwan Yang Jae-Cheol Jo Shin Young Hyun Hyeon-Seok Eom jeong-Ok Lee Ji Hyun Kwon Sang hoon Han Seung-Shin Lee Jae-Yong Kwak Se Hyung Kim Dae Sik Kim Ji Hyun Lee Sung Yong Oh Hun Mo Ryoo Hyo Jung Kim Won Seog Kim Division of Hematology-Oncology Department of MedicineChung-Ang UniversityDongjak-guSeoul 06973Korea Division of Hematology and Oncology Department of MedicineSamsung Medical Center Sungkyunkwan University School of MedicineGangnam-guSeoul 06351Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Korea National Health Insurance Corporation Ilsan Hospital Ilsandong-guGoyang 10444Korea Department of Hemato-Oncology Chonnam National University Hwasun HospitalChonnam National University Medical SchoolHwasunGwangju 58128Korea Department of Hematology and Oncology Ulsan University HospitalUniversity of Ulsan College of MedicineDong-guUlsan 44033Korea Department of Internal Medicine Yonsei University Wonju College of MedicineGangwon-DoWonju 26426Korea Department of Internal Medicine National Cancer CenterGoyang-si Gyeonggi-doGoyang 10408Korea Department of Internal Medicine Seoul National University Bundang HospitalBundang-guSeongnam 13620Korea Department of Internal Medicine ChungBuk National University HospitalChungbukCheongju 28644Korea Department of Internal Medicine Jeju National University HospitalJeju National University School of MedicineJeju 63241Korea Department of Hematology-Oncology Wonkwang University HospitalIksan-daeroIksan 54538Korea Department of Internal Medicine Jeonbuk National University Medical SchoolJeollabuk-doJeonju 54907Korea Division of Hematology-Oncology Department of Internal MedicineSoonchunhyang University College of MedicineBucheon HospitalWonmi-guBucheon 14584Korea Division of Hematology-Oncology Department of Internal MedicineKorea University Guro HospitalGuro-guSeoul 08308Korea Division of Hematology-Oncology Department of Internal MedicineDong-A University College of MedicineSeo-guBusan 49201Korea Department of Internal Medicine Division of Hematology-Oncology Catholic University of DaeguDaegu 42472Korea Division of Hematology-Oncology Department of Internal MedicineHallym U

Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustine,lenalidomide or bortezomib,mantle cell lymphoma(MCL)is still considered incurable and most patients experience relapse or refractory(RR)disease.

关键词： patients relapse lymphoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Wallenberg's Syndrome (Lateral Medullary Syndrome)

引用

介入放射学杂志 2004年第S1期13卷 172-172页

作者： Han jeong-hoon Huh Choon-Woong Sung Woo-Hyun Department of Neurosurgery Myongji St.s Mary's Hospital Seoul KoreaDepartment of Neurosurgery Myongji St.s Mary's Hospital Seoul KoreaDepartment of Neurosurgery Myongji St.s Mary's Hospital Seoul Korea

Objective The cause of Wallenberg’s Syndrome is the occlusion of vertebral artery(VA) or PICA. The purpose of this study was to present safe and feasibility of endovascular treatment of vertebral artery *** And Method A 65 year-old patient complained of nausea, vomiting, dizziness, dysarthria, left facial pain and thermal sensory loss, right hemibody pain and thermal sensory loss. Patients admitted to intensive care unit. MRI showed acute medullary infarction. Angiography showed right VA origin 82% stenosis and left VA obstruction. VA origin was treated with angioplasty and stenting. Results No major or minor complication occurred. Neurological status was stable after 7 days. Conclusions Angioplasty and stenting will be performed more widely and play an important role in the prevention of stroke.

关键词：

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study

引用

Cancer Communications 2019年第1期39卷 526-535页

作者： Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok-Hwan Yang Won Sik Lee Hyo Jung Kim Ho-Young Yhim Seong Hyun jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-Won Lee Jae hoon Lee Ho Sup Lee Ho-Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Republic of Korea Department of Hematology-Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology-Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology-Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology-Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology-Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment ***,extending the period of remission in MZL patients remains an essential *** multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further ***:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV ***(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week *** patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 *** primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment ***:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance ***(33%)patients had nodal *** R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,*** a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of *** LDH and the presence of B symptoms were found to be significant prognostic fac

关键词： Marginal zone Lymphoma Advanced stage Rituximab Cyclophosphamide Vincristine Maintenance Multicenter Open label Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

边缘区淋巴瘤晚期患者R-CVP后利妥昔单抗维持治疗的Ⅱ期研究:一项改善淋巴瘤生存协会(CISL)的研究

引用

癌症 2020年第3期39卷 118-128页

作者： Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok‑Hwan Yang Won Sik Lee Hyo Jung Kim Ho‑Young Yhim Seong Hyun jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung‑Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong‑Won Lee Jae hoon Lee Ho Sup Lee Ho‑Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa‑guSeoul 05505Republic of Korea Department of Hematology‑Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology‑Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多... 详细信息

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多中心、单臂、开放标签的Ⅱ期研究评估了对一线R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone;利妥昔单抗、环磷酰胺、长春新碱和泼尼松龙)治疗有反应的Ⅲ–Ⅳ期CD20阳性MZL患者进行利妥昔单抗维持治疗2年的生存率。本研究旨在明确R-CVP后利妥昔单抗维持治疗的策略是否有进一步研究的价值。方法在利妥昔单抗维持治疗之前,Ⅲ–Ⅳ期MZL患者应接受6–8周期的R-CVP一线治疗。每个周期为3周,第1 d静脉输注利妥昔单抗(375 mg/m^2)、环磷酰胺(750 mg/m^2)和长春新碱(1.4 mg/m^2;最大2 mg),第1–5 d口服泼尼松龙(100 mg)。对R-CVP治疗达到完全缓解(complete response,CR)、部分缓解(part response,PR)或疾病稳定(stable response,SD)的患者进行利妥昔单抗维持治疗,每8周静脉注射利妥昔单抗375mg/m^2,直到12个周期。主要终点为无进展生存期(progression-free surviva,PFS),次要终点为总生存期(overall survival,OS)和治疗安全性。结果共纳入47例患者,其中45(96%)例接受了利妥昔单抗维持治疗。15(33%)例患者有淋巴结MZL。在进行R-CVP一线治疗后,分别有20(44%)例、22(49%)例和3(7%)例的患者达到了CR、PR和SD。中位随访38.2个月后,患者的3年PFS率为81%。在利妥昔单抗维持治疗期间,R-CVP治疗后有6例PR和1例SD患者获得CR。LDH升高和B症状是PFS的重要预后因素(P=0.003),3年OS率为90%。利妥昔单抗维持治疗的耐受性良好,常见的治疗性不良事件为感觉性神经病(18%)、肌痛(13%)、疲劳(9%)和中性粒细胞减少(9%)。结论一线R-CVP治疗后利妥昔单抗维持治疗在Ⅲ–Ⅳ期MZL患者中不仅表现出较好的PFS,而且药物毒性反应评价良好。

关键词：边缘区淋巴瘤晚期利妥昔单抗环磷酰胺长春新碱维持多中心开放标签生存

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

韩国go mir——东临碣石,以观沧海

引用

国际纺织品流行趋势 2017年第3期 188-193页

作者： Kim suk heè Park jeong uk Song jun eui 高红杨念齐 Moon hoon建筑事务所

“东临碣石，以观沧海。水伺澹澹，山岛竦峙。”济州岛是韩国知名的旅游胜地，高大的汉拿山，黝黑的玄武岩，波澜的大海。基地临近著名的“龙头岩”，这给了设计师创作灵感。“Go”为业主的姓氏“高”，“mir”为韩文中的“龙”。店名... 详细信息

“东临碣石，以观沧海。水伺澹澹，山岛竦峙。”济州岛是韩国知名的旅游胜地，高大的汉拿山，黝黑的玄武岩，波澜的大海。基地临近著名的“龙头岩”，这给了设计师创作灵感。“Go”为业主的姓氏“高”，“mir”为韩文中的“龙”。店名、设计、景色相互交融。浑然天成。

关键词： mir 韩国旅游胜地创作灵感设计师济州岛玄武岩

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Publisher Correction to:Highly Elastic,Bioresorbable Polymeric Materials for Stretchable,Transient Electronic Systems

引用

Nano-Micro Letters 2024年第8期16卷 417-417页

作者： jeong‑Woong Shin Dong‑Je Kim Tae‑Min Jang Won Bae Han Joong hoon Lee Gwan‑Jin Ko Seung Min Yang Kaveti Rajaram Sungkeun Han Heeseok Kang Jun Hyeon Lim Chan‑Hwi Eom Amay JBandodkar Hanul Min Suk‑Won Hwang KU‑KIST Graduate School of Converging Science and Technology Korea University145 Anam‑roSeongbuk‑guSeoul 02841Republic of Korea SK Hynix 2091Gyeongchung‑daeroBubal‑eupIcheon‑siGyeonggi‑do 17336Republic of Korea Hanwha Systems Co. Ltd.188Pangyoyeok‑roBundang‑guSeongnam‑siGyeonggi‑do 13524Republic of Korea Department of Electrical and Computer Engineering North Carolina State UniversityRaleighNC 27606USA Center for Advanced Self‑Powered Systems of Integrated Sensors and Technologies(ASSIST) North Carolina State UniversityRaleighNC 27606USA Department of Integrative Energy Engineering Korea University145 Anam‑roSeongbuk‑guSeoul 02841Republic of Korea Biomaterials Research Center Korea Institute of Science and Technology(KIST)5 Hwarang‑ro 14‑gilSeongbuk‑guSeoul 02792Republic of Korea Semiconductor R&D Center Samsung Electronics Co.Ltd.Hwaseong‑siGyeonggi‑do 18448Republic of Korea Center for Advanced Biomolecular Recognition Biomedical Research DivisionKorea Institute of Science and Technology(KIST)Seoul 02792Republic of Korea

Due to typesetting mistake,Hanul Min was missed to be denoted as a corresponding author in the *** type-setter apologizes for *** original article has been *** Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use,sharing,adaptation,distribution and reproduction in any medium or format,as long as you give appropriate credit to the original author(s)and the source,provide a link to the Creative Commons licence,and indicate if changes were *** images or other third party material in this article are included in the article’s Creative Commons licence,unless indicated otherwise in a credit line to the *** material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use,you will need to obtain permission directly from the copyright holder.

关键词： Creative Elastic Highly

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：